Asplenia: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(47 intermediate revisions by 2 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Infobox_Disease
| Name          = Asplenia
| Image          =
| Caption        =
| DiseasesDB    =
| ICD10          = {{ICD10|D|73|0|d|70}}, {{ICD10|Q|89|0|q|80}}
| ICD9          = {{ICD9|289.59}}, {{ICD9|759.01}}
| ICDO          =
| OMIM          =  208530 
| OMIM_mult      = {{OMIM2|%271400}} {{OMIM2|208540}}
| MedlinePlus    =
| MeshID        =
}}
{{Asplenia}}
{{Asplenia}}
{{CMG}}{{AE}}
{{CMG}}{{AE}} {{Kalpana Giri}}  


{{SK}}  
{{SK}}  
Line 21: Line 8:


==[[Asplenia historical perspective|Historical Perspective]]==
==[[Asplenia historical perspective|Historical Perspective]]==
*In  421 BC, [[Hippocrates]] made the first description of the [[gross anatomy]] of the [[spleen]].<ref name="pmid17364987">{{cite journal| author=William BM, Corazza GR| title=Hyposplenism: a comprehensive review. Part I: basic concepts and causes. | journal=Hematology | year= 2007 | volume= 12 | issue= 1 | pages= 1-13 | pmid=17364987 | doi=10.1080/10245330600938422 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17364987  }} </ref>
*In  360 BC, [[Plato]], [[described]] the [[spleen]] as been constructed "with a view of keeping the [[liver]] [[bright]] and [[pure]].
*In 1899, [[Chauffard]] described that [[increased]] [[splenic]] activity is [[linked]] to [[hemolysis]], and in 1910, [[Sutherland and Brughard]] performed the first [[therapeutic splenectomy]] in a patient with hereditary spherocytosis.
*In 1913, [[Eppinger]] was the first to [[introduced]] the term [[hyposplenism]] to describe the [[post-splenectomy state]].
*In 1916, [[Kaznelson]] performed [[therapeutic splenectomy]] in a patient with [[idiopathic]] [[thrombocytopenic purpura]].
*In 1919, Morris and Bullock provided initial [[experimental]] evidence of the protective role of the [[spleen]] against [[infections]].<ref name="pmid21474172">{{cite journal| author=Di Sabatino A, Carsetti R, Corazza GR| title=Post-splenectomy and hyposplenic states. | journal=Lancet | year= 2011 | volume= 378 | issue= 9785 | pages= 86-97 | pmid=21474172 | doi=10.1016/S0140-6736(10)61493-6 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21474172  }} </ref>
*In 1935, [[Diggs]] provide a [[histological]] description of the [[spleen]] in [[sickle cell anemia]].<ref name="pmid17364987">{{cite journal| author=William BM, Corazza GR| title=Hyposplenism: a comprehensive review. Part I: basic concepts and causes. | journal=Hematology | year= 2007 | volume= 12 | issue= 1 | pages= 1-13 | pmid=17364987 | doi=10.1080/10245330600938422 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17364987  }} </ref>
*In 1952, King and Schumacker reported a series of cases of overwhelming [[post-splenectomy]] [[infections]] (OPSI) caused by [[encapsulated bacteria]].<ref name="pmid21474172">{{cite journal| author=Di Sabatino A, Carsetti R, Corazza GR| title=Post-splenectomy and hyposplenic states. | journal=Lancet | year= 2011 | volume= 378 | issue= 9785 | pages= 86-97 | pmid=21474172 | doi=10.1016/S0140-6736(10)61493-6 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21474172  }} </ref>
*In 1955, Rowley has demonstrated that [[splenectomized]] human beings fail to respond with a [[significant]] [[rise]] in [[antibody]] [[titer]] when an [[antigen]] is given intravenously.<ref name="pmid1228266">{{cite journal| author=Fachet J, Foris G| title=Enodotoxin-induced non-specific resistance to Trypanosoma equiperdum in neonatally thymectomized or splenectomized Wistar rats. | journal=Keio J Med | year= 1975 | volume= 24 | issue= 4 | pages= 347-53 | pmid=1228266 | doi=10.2302/kjm.24.347 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1228266  }} </ref>
*In 1955, Dameshek coined the term [[hyposplenism]] to describe a patient with [[coeliac disease]].<ref name="pmid21474172">{{cite journal| author=Di Sabatino A, Carsetti R, Corazza GR| title=Post-splenectomy and hyposplenic states. | journal=Lancet | year= 2011 | volume= 378 | issue= 9785 | pages= 86-97 | pmid=21474172 | doi=10.1016/S0140-6736(10)61493-6 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21474172  }} </ref>
*In 1969, Pearson et al,from USA, was the first to [[discover]] the term [[functional hypoplasia]], a few decades ago when he identified some children suffering from [[sickle cell disease]], who presented with the same [[clinical]] course as in [[splenectomised]] patients.<ref name="pmid25125944">{{cite journal| author=Kirkineska L, Perifanis V, Vasiliadis T| title=Functional hyposplenism. | journal=Hippokratia | year= 2014 | volume= 18 | issue= 1 | pages= 7-11 | pmid=25125944 | doi= | pmc=4103047 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25125944  }} </ref>


==[[Asplenia classification|Classification]]==
==[[Asplenia classification|Classification]]==


==[[Asplenia pathophysiology|Pathophysiology]]==
==[[Asplenia pathophysiology|Pathophysiology]]==
===Physiology===
The [[spleen]] consists of three [[functional]] inter-related [[compartments]]: [[red pulp]], [[white pulp]], [[marginal zone]]. The red pulp is a [[sponge-like]] structure filled with [[blood]] flowing through [[sinuses]] and [[cords]] functions as a filter for [[blood elements]].<ref name="pmid21474172">Di Sabatino A, Carsetti R, Corazza GR (2011) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=21474172 Post-splenectomy and hyposplenic states.] ''Lancet'' 378 (9785):86-97. [http://dx.doi.org/10.1016/S0140-6736(10)61493-6 DOI:10.1016/S0140-6736(10)61493-6] PMID: [https://pubmed.gov/21474172 21474172]</ref> The [[white pulp]] consists primarily of [[lymphatic tissue]] creating structures called [[germinal centers]] which contain [[lymphocytes]] (activated [[B-lymphocytes]] among others), [[macrophages]], and [[dendritic cells]]. They are situated in direct contact with [[splenic arterioles]], branches of the [[splenic artery]]. Another region of the [[white pulp]] is that the [[periarteriolar]] [[lymphatic sheath]], which consists of [[nodules]] containing mostly [[B lymphocytes]]. The [[marginal zone]] surrounds the [[white pulp]] and consists of [[blood vessels]], [[macrophages]], and [[specialized B cells]].<ref name="pmid25125944">{{cite journal| author=Kirkineska L, Perifanis V, Vasiliadis T| title=Functional hyposplenism. | journal=Hippokratia | year= 2014 | volume= 18 | issue= 1 | pages= 7-11 | pmid=25125944 | doi= | pmc=4103047 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi? dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25125944  }} </ref> The [[primary physiologic]] role of [[spleen]] is the [[filtration]] and processing of [[senescent blood cells]], predominantly [[red blood cells]] and [[immunologically]] helps protect against [[encapsulated microorganisms]] and response to [[infectious pathogens]]. It contains both [[hematopoietic]] and [[lymphopoietic]] elements, which provides a basis for [[extramedullary hematopoiesis]] when necessary.
===Pathology===
The [[spleen]] plays [[integral roles]] in the [[immune system]] and [[reticuloendothelial systems]]. It also [[modulates]] the [[inflammatory]] and [[coagulation cascades]].<ref name="pmid32247651">{{cite journal| author=Long B, Koyfman A, Gottlieb M| title=Complications in the adult asplenic patient: A review for the emergency clinician. | journal=Am J Emerg Med | year= 2021 | volume= 44 | issue=  | pages= 452-457 | pmid=32247651 | doi=10.1016/j.ajem.2020.03.049 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32247651  }} </ref> It is understood that [[Asplenia]] is a variety of clinical settings, and it can refer to an [[anatomic]] absence of the [[spleen]] or [[functional asplenia]] secondary to a variety of [[disease]] states.  The absence of a [[spleen]] is a well-known [[risk factor]] for severe [[bacterial infections]], especially due to [[encapsulated bacteria]]. The spleen contains 2 types of tissues: [[white pulp]] and [[red pulp]]. The [[white pulp]] is rich in [[T-cell lymphocytes]], [[naïve B-cell lymphocytes]], and [[macrophages]]. The [[antigen-presenting cells]] (APC) can enter the [[white pulp]] and activate [[T cells]], which in turn activate [[naïve B cells]] and [[differentiate]] into [[plasma cells]] that generate [[immunoglobulin M]] [[antibodies]] followed by [[immunoglobulin G]] [[antibodies]]. [[B cells]] can also act as [[antigen-presenting cells]] and has a [[phagocytic function]] to help [[opsonize]] [[encapsulated bacteria]]. About half of the [[total B cells]] in the [[blood]] [[express]] the [[memory marker]] [[CD27]] and carry [[somatic mutations]], and are therefore thought to be [[memory B cells]]. There are two types of [[memory B cells]] in human beings: [[switched memory B cells]] and [[IgM memory B cells]]. [[Switched memory B cells]], which are the final product of [[germinal center reactions]], produce [[high-affinity antibodies]] and have a [[protective]] function against [[infection]]. [[IgM memory B cells]], need the [[spleen]] for their [[survival]] and [[generation]] and have the ability to produce [[natural antibodies]]. They also produce [[antibodies]] against [[Streptococcus pneumonia]], [[Neisseria meningitidis]], and [[Haemophilus influenzae type b]]. They can initiate [[T-cell-independent]] [[immune responses]] on [[infection]] or [[vaccination]] with [[capsular polysaccharide antigens]].<ref name="pmid21474172">{{cite journal| author=Di Sabatino A, Carsetti R, Corazza GR| title=Post-splenectomy and hyposplenic states. | journal=Lancet | year= 2011 | volume= 378 | issue= 9785 | pages= 86-97 | pmid=21474172 | doi=10.1016/S0140-6736(10)61493-6 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21474172  }} </ref> The [[red pulp]] has [[macrophages]] and is responsible for [[filtering]] damaged, older [[red blood cells]] as well as [[phagocytosing]] [[opsonized bacteria]]. Due to this role of removing [[damaged erythrocytes]], the [[spleen]] also plays an important role in the [[defense against]] [[intraerythrocytic]] [[parasitic infections]] such as [[malaria]] and [[Babesia]].<ref name="pmid33275684">{{cite journal| author=Lee GM| title=Preventing infections in children and adults with asplenia. | journal=Hematology Am Soc Hematol Educ Program | year= 2020 | volume= 2020 | issue= 1 | pages= 328-335 | pmid=33275684 | doi=10.1182/hematology.2020000117 | pmc=7727556 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=33275684  }} </ref>


==[[Asplenia causes|Causes]]==
==[[Asplenia causes|Causes]]==
Asplenia is caused by either congenital, acquired conditions, or functional.
===Common Causes===
===Acquired===
*'''Acquired asplenia''' associated after [[trauma]] or [[surgery]], is one of the commonest cause of the absence of [[splenic tissue]].<ref name="pmid26557043">{{cite journal| author=Erdem SB, Genel F, Erdur B, Ozbek E, Gulez N, Mese T| title=Asplenia in children with congenital heart disease as a cause of poor outcome. | journal=Cent Eur J Immunol | year= 2015 | volume= 40 | issue= 2 | pages= 266-9 | pmid=26557043 | doi=10.5114/ceji.2015.52841 | pmc=4637402 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26557043  }} </ref>
*'''Functional asplenia''' include [[diseases]] such as [[sickle cell (SC) disease]], [[hemoglobin SC disease]] and [[sickle beta-thalassemia]].<ref name="pmid18564289">{{cite journal| author=Thiruppathy K, Privitera A, Jain K, Gupta S| title=Congenital asplenia and group B streptococcus sepsis in the adult: case report and review of the literature. | journal=FEMS Immunol Med Microbiol | year= 2008 | volume= 53 | issue= 3 | pages= 437-9 | pmid=18564289 | doi=10.1111/j.1574-695X.2008.00422.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18564289  }} </ref>
*'''Hyposplenia''' occurs due to [[medical conditions]] such as [[chronic liver disease]], [[human immunodeficiency syndrome (HIV)]], [[malignancies]], [[thalassemia]], [[celiac disease]], [[ulcerative colitis]], [[sarcoidosis]], [[amyloidosis]], [[lupus]], [[rheumatoid arthritis]].<ref name="pmid32247651">{{cite journal| author=Long B, Koyfman A, Gottlieb M| title=Complications in the adult asplenic patient: A review for the emergency clinician. | journal=Am J Emerg Med | year= 2021 | volume= 44 | issue=  | pages= 452-457 | pmid=32247651 | doi=10.1016/j.ajem.2020.03.049 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32247651  }} </ref>
===Less Common Causes===
===Congenital===
*'''Congenital asplenia''' may be [[isolated]] or usually seen as a [[clinical syndrome]] such as [[ivemark syndrome]]. This [[syndrome]] is classified under [[heterotaxy syndrome]]. It is associated with [[malformation]] of the [[heart]], and abnormal arrangements of organs of the chest and abdomen along with [[asplenia]] or [[hypoplasia]] of the [[spleen]].
*'''Isolated asplenia''' are rare and etiology was [[genetic]], due to [[mutations]] in the [[gene RPSA]], which encodes [[ribosomal protein SA]], cause more than half of the cases of [[isolated congenital asplenia]], which was first discovered in 2013.
*In '''heterotaxy syndrome''' Two human [[genes]], [[connexin 43]] and [[ZIC3]], have been shown to be involved.
*congenital asplenia a very rare anomaly that has been reported in both infants and adults.
*'''Infantile''' cases are almost invariably associated with serious congenital malformations of the [[cardiovascular]], [[gastrointestinal]], and [[pulmonary]] systems that are not compatible with long life.
*These include [[atrioventricular]] communist, [[pulmonary stenosis]] or [[atresia]], anomalies of the [[aorta]] and [[great vessels]], complete or partial [[situs in versus]], [[anomalies]] of the [[mesenteric]] and [[accessory lobes of the lungs]].
*In the '''adult''' [[splenic]] [[agenesis]] is usually an isolated and unexpected finding.<ref name="pmid13322226">{{cite journal| author=MYERSON RM, KOELLE WA| title=Congenital absence of the spleen in an adult; report of a case associated with recurrent Waterhouse-Friderichsen syndrome. | journal=N Engl J Med | year= 1956 | volume= 254 | issue= 24 | pages= 1131-2 | pmid=13322226 | doi=10.1056/NEJM195606142542406 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=13322226  }} </ref>


==[[Asplenia differential diagnosis|Differentiating Asplenia from other Diseases]]==
==[[Asplenia differential diagnosis|Differentiating Asplenia from other Diseases]]==
Line 69: Line 20:


==[[Asplenia risk factors|Risk Factors]]==
==[[Asplenia risk factors|Risk Factors]]==
===Common Risk Factors===
*Common risk factors in the development of asplenia include:
**[[Trauma]] <ref name="pmid26557043">{{cite journal| author=Erdem SB, Genel F, Erdur B, Ozbek E, Gulez N, Mese T| title=Asplenia in children with congenital heart disease as a cause of poor outcome. | journal=Cent Eur J Immunol | year= 2015 | volume= 40 | issue= 2 | pages= 266-9 | pmid=26557043 | doi=10.5114/ceji.2015.52841 | pmc=4637402 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26557043  }} </ref>
**[[Atraumatic]] indication for [[splenectomy]] includes:<ref name="pmid27018168">{{cite journal| author=Browning MG, Bullen N, Nokes T, Tucker K, Coleman M| title=The evolving indications for splenectomy. | journal=Br J Haematol | year= 2017 | volume= 177 | issue= 2 | pages= 321-324 | pmid=27018168 | doi=10.1111/bjh.14060 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27018168  }} </ref>
***[[malignancy]]
***[[hematological autoimmune disorder]]
****[[Idiopathic Thrombocytopenic Purpura (ITP)]]
****[[Autoimmune Hemolytic Anemia (AIHA)]]
**[[Surgery]]: includes
***[[unexplained splenomegaly]]
***[[autoimmune]]
***[[malignant]]
===Less Common Risk Factors===
*Less common risk factor include:
**[[mutations]] in the [[gene RPSA]], is a risk factor for [[Isolated asplenia]].<ref name="pmid25840456">{{cite journal| author=Bolze A| title=[Connecting isolated congenital asplenia to the ribosome]. | journal=Biol Aujourdhui | year= 2014 | volume= 208 | issue= 4 | pages= 289-98 | pmid=25840456 | doi=10.1051/jbio/2015001 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25840456  }} </ref>
**Two human [[genes]], [[connexin 43]] and [[ZIC3]], is a risk factor for [[heterotaxy syndrome]].<ref name="pmid19618213">{{cite journal| author=Ahmed SA, Zengeya S, Kini U, Pollard AJ| title=Familial isolated congenital asplenia: case report and literature review. | journal=Eur J Pediatr | year= 2010 | volume= 169 | issue= 3 | pages= 315-8 | pmid=19618213 | doi=10.1007/s00431-009-1030-0 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19618213  }} </ref>


==[[Asplenia screening|Screening]]==
==[[Asplenia screening|Screening]]==
[[screening]] for [[asplenia]] is by the [[detection]] of [[Howell-Jolly bodies]] (ie, [[erythrocytes]] with [[nuclear remnants]]) is recommended.
<ref name="pmid2125541">{{cite journal| author=Corazza GR, Ginaldi L, Zoli G, Frisoni M, Lalli G, Gasbarrini G | display-authors=etal| title=Howell-Jolly body counting as a measure of splenic function. A reassessment. | journal=Clin Lab Haematol | year= 1990 | volume= 12 | issue= 3 | pages= 269-75 | pmid=2125541 | doi=10.1111/j.1365-2257.1990.tb00037.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2125541  }} </ref>


==[[Asplenia natural history, complications and prognosis|Natural History, Complications and Prognosis]]==
==[[Asplenia natural history, complications and prognosis|Natural History, Complications and Prognosis]]==
===Natural History===
*Functional asplenia is most common in [[sickle cell disease]] and [[occurs]] within the [[first 3-5 years]] of [[life]].<ref name="pmid32247651">{{cite journal| author=Long B, Koyfman A, Gottlieb M| title=Complications in the adult asplenic patient: A review for the emergency clinician. | journal=Am J Emerg Med | year= 2021 | volume= 44 | issue=  | pages= 452-457 | pmid=32247651 | doi=10.1016/j.ajem.2020.03.049 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32247651  }} </ref>
===Complications===
Common complications of [disease name] include:
*[[overwhelming post-splenectomy infection (OPSI)]]<ref name="pmid25125944">{{cite journal| author=Kirkineska L, Perifanis V, Vasiliadis T| title=Functional hyposplenism. | journal=Hippokratia | year= 2014 | volume= 18 | issue= 1 | pages= 7-11 | pmid=25125944 | doi= | pmc=4103047 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25125944  }} </ref>
*[[Infection]] with [[encapsulated microorganisms]] ([[eg streptococcal pneumonia]]), [[parasitic infections]] such as [[babesiosis]], [[malaria]].
*[[Waterhouse-Friedrichsen syndrome]] and [[Purpura fulminans]] <ref name="pmid27583208">{{cite journal| author=Hale AJ, LaSalvia M, Kirby JE, Kimball A, Baden R| title=Fatal purpura fulminans and Waterhouse-Friderichsen syndrome from fulminant Streptococcus pneumoniae sepsis in an asplenic young adult. | journal=IDCases | year= 2016 | volume= 6 | issue=  | pages= 1-4 | pmid=27583208 | doi=10.1016/j.idcr.2016.08.004 | pmc=4995527 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27583208  }} </ref>
*[[Arterial thrombosis]]: includes [[coronary artery disease]] <ref name="pmid32247651">{{cite journal| author=Long B, Koyfman A, Gottlieb M| title=Complications in the adult asplenic patient: A review for the emergency clinician. | journal=Am J Emerg Med | year= 2021 | volume= 44 | issue=  | pages= 452-457 | pmid=32247651 | doi=10.1016/j.ajem.2020.03.049 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32247651  }} </ref>
*[[Venous thrombosis]]: includes [[deep vein thrombosis]], [[pulmonary embolism]], [[splenic]] and [[portal vein thrombosis]]
*[[Pulmonary hypertension]], [[associated] with [[right ventricular dysfunction]].


==Diagnosis==
==Diagnosis==
Line 111: Line 29:


==Treatment==
==Treatment==
[[Asplenia medical treatment|Medical Therapy]] | [[Asplenia surgical techniques|Surgery]] | [[Asplenia interventions|Interventions]] | [[Asplenia primary prevention|Primary Prevention]] | [[Asplenia secondary prevention|Secondary Prevention]] | [[Asplenia cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Asplenia future or investigational therapies|Future or Investigational Therapies]]
[[Asplenia medical treatment|Medical Therapy]] | [[TAsplenia surgical techniques|Surgery]] | [[Asplenia primary prevention|Primary Prevention]] | [[Asplenia secondary prevention|Secondary Prevention]] | [[Asplenia cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Asplenia future or investigational therapies|Future or Investigational Therapies]]
==Medical Therapy==
===Emergency Medical Management of suspected sepsis in Asplenic patient===
Asplenia can cause [[sepsis]] and require immediate management:<ref name="pmid24855431">{{cite journal| author=Salvadori MI, Price VE, Canadian Paediatric Society, Infectious Diseases and Immunization Committee| title=Preventing and treating infections in children with asplenia or hyposplenia. | journal=Paediatr Child Health | year= 2014 | volume= 19 | issue= 5 | pages= 271-8 | pmid=24855431 | doi= | pmc=4029242 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24855431  }} </ref>
*Children with [[asplenia]] for every [[febrile illness]], must be seen by a physician immediately.
*[[Sepsis]] in individuals with [[asplenia]] or [[hyposplenia]] is a [[medical emergency]] as these [[patients]] can die within several hours of [[fever]] onset despite appearing well initially.
*[[Administration]] of [[antibiotic]] therapy should not be delayed and [[blood culture]] should be performed unless there is an obvious [[nonbacterial source]].
*[[Ceftriaxone]]: [[100 mg/kg/dose]], [[(maximum 2 g/dose)]] should be given in all [[asplenic patients]].
*[[Administer]] both [[ceftriaxone]] and [[vancomycin]] (60 mg/kg/day in divided doses every 6 h) in case of [[intermediate]] or [[high penicillin-resistant pneumococci]].
*If the [[patient]] is treated in a [[clinic]] or [[office setting]], refer [[immediately]] to the nearest [[emergency department]].
*Clinical [[deterioration]] can be rapid even after [[antibiotic administratin]] so changes in [[antibiotics]] should be done after [[culture reports]] available.
*[[Vancomycin]] and [[ciprofloxacin]] can be used if the patient has an [[allergy]] to [[penicillin]] or [[cephalosporin]]. Changes in [[antibiotics]] should be done after [[culture]] reports available.
*According to the [[Surviving]] [[Sepsis]] [[Campaign]] guidelines, to avoid poor outcomes, patients suspected of [[sepsis]] should be started on [[antibiotics]] within 1 hour and as per standard [[sepsis]] guidelines, [[aggressive]] [[intravenous (IV)]] [[hydration]] should also be promptly [[initiated]] as a part of [[supportive care]].<ref name="pmid28101605">{{cite journal| author=Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R | display-authors=etal| title=Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. | journal=Intensive Care Med | year= 2017 | volume= 43 | issue= 3 | pages= 304-377 | pmid=28101605 | doi=10.1007/s00134-017-4683-6 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28101605  }} </ref>
*Also, [[asplenic]] [[patients]] are prone to [[developing]] [[septic shock]], they may require [[vasopressors]] to maintain their [[blood pressure]] and if patients develop [[respiratory failure]], [[mechanical ventilation]] may be [[necessary]] for [[certain]] [[circumstances]].
 
==Surgery==
The mainstay of [[treatment]] for [[asplenia]] is [[medical therapy]] and [[prevention]].<ref name="pmid11253134">{{cite journal| author=Waghorn DJ| title=Overwhelming infection in asplenic patients: current best practice preventive measures are not being followed. | journal=J Clin Pathol | year= 2001 | volume= 54 | issue= 3 | pages= 214-8 | pmid=11253134 | doi=10.1136/jcp.54.3.214 | pmc=1731383 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11253134  }} </ref>
 
==Primary prevention==
===Vaccination===
*Vaccination against these encapsulated bacteria is recommended to prevent asplenia patients from severe infection. Up to 87% of asplenic patients were found to have been infected with Streptococcus pneumoniae, one of the most common bacterial pathogen leading to infection in patients with asplenia.
*[[Vaccinations]] are also recommended before [[splenectomy]] and after the surgical removal. For those with [[functional asplenia]] or [[autosplenectomy]], it is also advised to continue aggressive [[vaccination schedules]]. It is recommended that patients should be given the [[pneumococcal conjugate vaccine (PCV-13)]] 8 weeks in advance, as well as the [[pneumococcal polysaccharide vaccine (PPSV-23)]], [[Haemophilus influenzae type B vaccine (Hib)]], and the [[quadrivalent meningococcal]] [[conjugate vaccine]] 14 days before planned surgery for [[splenectomy]].
*Apart from all these [[vaccines]], patients should be [[encouraged]] to [[receive]] [[influenza vaccine]], [[annual vaccination]] against the common [[strains]] of [[influenza]].<ref name="pmid26130882">{{cite journal| author=Huebner ML, Milota KA| title=Asplenia and fever. | journal=Proc (Bayl Univ Med Cent) | year= 2015 | volume= 28 | issue= 3 | pages= 340-1 | pmid=26130882 | doi=10.1080/08998280.2015.11929267 | pmc=4462215 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26130882  }} </ref>
 
===Antibiotic Prophylaxis===
*Only [[Immunizations]] do not [[protect against]] [[infections]] with [[encapsulated bacteria]], [[antibiotic prophylaxis]] Should be given.<ref name="pmid24855431">{{cite journal| author=Salvadori MI, Price VE, Canadian Paediatric Society, Infectious Diseases and Immunization Committee| title=Preventing and treating infections in children with asplenia or hyposplenia. | journal=Paediatr Child Health | year= 2014 | volume= 19 | issue= 5 | pages= 271-8 | pmid=24855431 | doi= | pmc=4029242 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24855431  }} </ref>
**'''For children'''
***All [[patients]] younger than [[five years]] of age should receive [[antibiotic prophylaxis]].
***'''Birth to three months''': [[Escherichia coli]], [[Klebsiella]] are of concern in this [[age group]].
****[[Amoxicillin]] or [[clavulanate]] 10 mg/kg/dose PO q12h, with [[penicillin VK]] 125 mg per dose PO q12h OR [[amoxicillin]] 10 mg/kg/dose q12h, as an [[alternative]] if not tolerated.
***'''more than 3 months to five years'''
****[[Penicillin]] VK 125 mg per dose PO q12h OR [[amoxicillin]] 10 mg/kg/dose PO q12h.
****[[Liquid amoxicillin]] tastes better and may be [[better tolerated]] than [[liquid penicillin]].
***'''more than 5 years'''
****[[Penicillin V]] 250 mg or 300 mg per dose  q12h OR [[amoxicillin]] 250 mg per dose q12h.
****For [[penicillin]], 250 mg is a convenient dose for [[suspension]] but [[tablets]] are only available as 300 mg
*The [[infectious]] [[risk]] in [[asplenic]] patients is high during their [[entire life]] but it is highest during the first 2 years following [[splenectomy]] and the [[risk]] [[decreases]] over time.<ref name="pmid32787857">{{cite journal| author=Quéffélec C, Billet L, Duffau P, Lazaro E, Machelart I, Greib C | display-authors=etal| title=Prevention of infection in asplenic adult patients by general practitioners in France between 2013 and 2016 : Care for the asplenic patient in general practice. | journal=BMC Fam Pract | year= 2020 | volume= 21 | issue= 1 | pages= 163 | pmid=32787857 | doi=10.1186/s12875-020-01237-3 | pmc=7425533 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32787857  }} </ref>
*Along with [[vaccination]], [[antibiotic prophylaxis]] should be given.
*Long term [[prophylactic therapy]]  [[oral antibiotic]] [[penicillin V]], or [[erythromycin]] in case of allergy, is required for at least [[2 years]] after [[splenectomy]] to cover the period during which the [[infectious]] risk is highest.
 
===Malaria Prophylaxis===
*[[Asplenic]] and [[hyposplenic]] children must be advised of their [[increased]] [[risk]] of [[severe malaria]] and also take [[malaria prophylaxis]] as appropriate for their age and the type of [[malaria]] found in the area to which they are [[travelling]] and they should always [[seek]] [[travel advice]].<ref name="pmid19750611">{{cite journal| author=Committee to Advise on Tropical Medicine and Travel (CATMAT)| title=Canadian recommendations for the prevention and treatment of malaria among international travellers--2009. | journal=Can Commun Dis Rep | year= 2009 | volume= 35 Suppl 1 | issue=  | pages= 1-82 | pmid=19750611 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19750611  }} </ref>
 
==Secondary prevention==
Effective measures for the secondary prevention of asplenia include:
 
*[[Patient]] should carry an [[alert card]] or [[bracelet]] and an [[up-to-date]] [[vaccination record]].<ref name="pmid32759171">{{cite journal| author=O'Neill NE, Baker J, Ward R, Johnson C, Taggart L, Sholzberg M| title=The development of a quality improvement project to improve infection prevention and management in patients with asplenia or hyposplenia. | journal=BMJ Open Qual | year= 2020 | volume= 9 | issue= 3 | pages=  | pmid=32759171 | doi=10.1136/bmjoq-2019-000770 | pmc=7410002 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32759171  }} </ref>
*Adult with [[asplenia]], if unable to seek [[medical attention]] within 2 hours, should have [[access]] to [[preprescribed antibiotics]] which should be taken at [[fever]] onset.
*The risk of [[infection]] can be significantly reduced by using [[systematic]], [[long-term approaches]] to care for [[asplenic patients]].
*[[Patient]] and [[family education program]] that addresses the [[risk]] of [[infection]] in these at-risk [[patients]].<ref name="pmid33275684">{{cite journal| author=Lee GM| title=Preventing infections in children and adults with asplenia. | journal=Hematology Am Soc Hematol Educ Program | year= 2020 | volume= 2020 | issue= 1 | pages= 328-335 | pmid=33275684 | doi=10.1182/hematology.2020000117 | pmc=7727556 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=33275684  }} </ref>
 
*


==Case Studies==
==Case Studies==
[[Asplenia case study one|Case #1]]
[[Asplenia case study one|Case #1]]
{{Hematology}}
{{Phakomatoses and other congenital malformations not elsewhere classified}}
[[de:Asplenie]]
[[nl:Asplenie]]
[[fi:Asplenia]]
{{WikiDoc Help Menu}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
[[Category:Medicine]]
[[Category:Medicine]]
[[Category:Oncology]]
[[Category:Oncology]]
Line 185: Line 40:
[[Category:Immunology]]
[[Category:Immunology]]
[[Category:Hematology]]
[[Category:Hematology]]
<references />

Latest revision as of 04:39, 9 September 2021

Asplenia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Asplenia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Asplenia On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Asplenia

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Asplenia

CDC on Asplenia

Asplenia in the news

Blogs on Asplenia

Directions to Hospitals Treating Asplenia

Risk calculators and risk factors for Asplenia

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Kalpana Giri, MBBS[2]

Synonyms and keywords:

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Asplenia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic study of choice | History and Symptoms | Physical Examination | Laboratory Findings | Electrocardiogram | X-Ray Findings | Echocardiography and Ultrasound | CT-Scan Findings | MRI Findings | Other Imaging Findings | Other Diagnostic Studies

Treatment

Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies

Case Studies

Case #1